UNH UnitedHealth Group Incorporated
Trend channel, buy level and 3-month target. Information only, not financial advice.
Inside the channel · 9-month channel rising
Price is between the lines.
- 9-month channel read from
- US$360.10 – US$581.66 · rising, +71% a year
- 12-month channel
- US$383.97 – US$539.98 · rising, +37% a year
- Price in channel
- 21% (0% = floor, 100% = ceiling)
- Ceiling overhead
- US$539.98
- Turns bearish below
- US$360.10
What broke this trend
- The fall
- -61% from US$600.1711 Nov 2024 → 1 Aug 2025
- Whose problem it was
- This company0 of 2 Medical - Healthcare Plans peers fell with it
- Does it resolve?
- Unsettled too close to a coin toss on the record to call
- Regained so far
- 48%of what it lost
- What the record says
- 53% of 529 comparable falls came back, typically in 148 days measured across every stock we hold history for, its peer group being too small
Fell -61% (11 Nov 2024 → 1 Aug 2025); regained 48% so far; company-specific.
Reported at the time: Unpacking the Latest Options Trading Trends in UnitedHealth Group — 11 Nov 2024
Price history, with the path projected 3 months forward
Updated 3:04 PM ET (21 h ago)
- Daily close
- Upper trend line (9 months)
- Lower trend line (9 months)
- The same lines over the last 12 months
- Dashed after today: projected 3 months
- Our buy
- Our target
Suggested path
Buy at or below
US$377.61
level as at 7 Dec 2026
Our target
US$407.82
by 2 Nov 2026
Projected move
8.0%
gross, before costs
Price is between our buy and target.
Target: UNH's usual move size (8.0%), the best return per day on this path.
This move size: reached in 57% of 10 past stretches, typically in 41 days. (0.20% per day)
11 settled calls · 8 reached target (72.7%) · average best move 8.8%. See the full record.
- Upper line touches
- 2
- Lower line touches
- 2
- Fit confidence
- 80%
- Fitted
- 1 Nov 2026
Company information
About UnitedHealth Group Incorporated
UnitedHealth Group Incorporated (UNH) operates as a comprehensive healthcare enterprise across the United States, structuring its diverse services into four key divisions: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment provides a wide array of health benefit plans and consumer-focused services. These offerings cater to a broad spectrum of clients, including large national corporations, public sector employers, mid-sized and small businesses, and individual consumers. It also delivers specialized health coverage and wellness programs tailored for individuals aged 50 and older, addressing their needs for preventive and acute care, chronic disease management, and other age-specific health issues. This division further encompasses Medicaid plans, children's health insurance, dental benefits, and various hospital and clinical services. Optum Health focuses on delivering direct healthcare solutions and management services. It facilitates access to networks of specialist care providers, offers health management programs, direct care delivery, consumer engagement initiatives, and financial services. Its diverse clientele includes individuals (served directly through care systems), employers, insurance payers, and government organizations. Optum Insight specializes in providing technology, information, and consulting services to the healthcare industry. Its offerings include software and data products, advisory consulting arrangements, and outsourced managed services. Clients span hospital systems, physicians, health plans, governmental bodies, life sciences companies, and other relevant organizations. Finally, Optum Rx handles the company's pharmaceutical care services. This segment manages retail pharmacy networks, provides home prescription delivery, and offers specialty and compounding pharmacy capabilities. Leveraging its purchasing power and clinical expertise, Optum Rx also develops advanced programs related to step therapy, formulary management, medication adherence, and integrated disease and drug therapy management. UnitedHealth Group Incorporated, founded in 1977, has its corporate headquarters located in Minnetonka, Minnesota.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Plans
- CEO
- Stephen J. Hemsley
- Employees
- 390,000
- Country
- US
Scorecard
Our own scores from the fundamentals below (not Morningstar ratings).
- Valuation
- 62/100
- Profitability
- 28/100
- Financial health
- 36/100
- Cash generation
- 39/100
Key statistics
- Market cap
- US$381.46B
- Enterprise value
- US$429.95B
- Beta
- 0.61
- Avg volume
- 5.45M
- Revenue per share
- 498.51
- Dividend yield
- 2.13%
- 52-week range
- 255.97-461.62
- Exchange
- NYSE
Key ratios
- P/E (TTM)
- 24.26
- PEG
- -2.71
- Price / sales
- 0.85
- Price / book
- 3.68
- EV / EBITDA
- 15.36
- Gross margin
- 22.81%
- Operating margin
- 5.32%
- Net margin
- 3.53%
- Current ratio
- 0.74
- Quick ratio
- 0.74
- Debt / equity
- 0.71
- Interest cover
- 6.21
Income statement
| Year | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 | US$447.57B | US$82.92B | US$18.96B | US$12.06B | US$13.23 |
| 2024 | US$400.28B | US$89.40B | US$32.29B | US$14.40B | US$15.51 |
| 2023 | US$371.62B | US$90.96B | US$32.36B | US$22.38B | US$23.86 |
| 2022 | US$324.16B | US$79.62B | US$28.43B | US$20.12B | US$21.18 |
| 2021 | US$287.60B | US$69.65B | US$23.97B | US$17.29B | US$18.08 |
Balance sheet
| Year | Total assets | Total liabilities | Total equity |
|---|---|---|---|
| 2025 | US$309.58B | US$207.88B | US$94.11B |
| 2024 | US$298.28B | US$195.69B | US$92.66B |
| 2023 | US$273.72B | US$174.80B | US$88.76B |
| 2022 | US$245.71B | US$159.36B | US$77.77B |
| 2021 | US$212.21B | US$135.73B | US$71.76B |
Cash flow
| Year | Operating cash flow | Free cash flow | Net income |
|---|---|---|---|
| 2025 | US$19.70B | US$16.07B | US$12.81B |
| 2024 | US$24.20B | US$20.70B | US$15.24B |
| 2023 | US$29.07B | US$25.68B | US$22.38B |
| 2022 | US$26.21B | US$23.40B | US$20.12B |
| 2021 | US$22.34B | US$19.89B | US$17.29B |
EPS forecasts
| Period | Est. EPS | Est. revenue | Analysts |
|---|---|---|---|
| 2025 | US$16.32 | US$447.86B | 21 |
| 2026 | US$20.56 | US$448.02B | 17 |
| 2027 | US$23.39 | US$463.15B | 18 |
| 2028 | US$27.26 | US$488.01B | 15 |
| 2029 | US$31.31 | US$510.64B | 9 |
| 2030 | US$34.92 | US$543.01B | 6 |
Analyst view
- Target (mean)
- US$478.35
- Target (high)
- US$529.00
- Target (low)
- US$380.00
- Strong buy
- 0
- Buy
- 43
- Hold
- 7
- Sell
- 2
Trend lines are fitted to past swing highs and lows and may not continue. Information only, not financial advice.